x and 6-sulfo-sLe x did not support any Siglec-8 binding at the highest concentration tested (300 pmol/spot). We conclude that Siglec-8 binds preferentially to the sLe x structure bearing an additional sulfate ester on the galactose 6-hydroxyl.
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are a recently designated family of cell surface molecules that are a subset of the immunoglobulin (Ig) gene superfamily (1) (2) (3) . Siglecs differ from traditional Ig superfamily members in several ways. Although their extracellular domains contain a variable number of C2-set Ig domains, unlike other Ig superfamily members, Siglecs possess an NH 2 -terminal V-set Ig domain that binds sialylated structures (4 -8) . In addition, Siglec cytoplasmic domains typically contain multiple tyrosine residues, including some with consensus immunoreceptor tyrosine-based inhibitory motifs (1) . This suggests that Siglecs possess signal transduction activity. Direct evidence of signaling has already been shown for several human Siglecs (9 -13) .
Siglec-8 (alternatively named SAF-2 (sialoadhesin family-2)) was discovered by CD33 homology screening of expressed sequence tag sequences from a human eosinophil cDNA library (14, 15) . The highest levels of homology are found between Siglec-8 and Siglec-3 (49%), Siglec-5 (42%), and Siglec-7 (68%), with virtually all of the homology due to similarities in the extracellular and transmembrane regions. Subsequently, a splice variant of Siglec-8, termed Siglec-8L, which contains an identical extracellular domain but a longer cytoplasmic tail possessing two tyrosine-based motifs, was discovered from human genomic DNA (16, 17) . Additional experiments using monoclonal antibodies revealed that Siglec-8 is expressed not only on the surface of eosinophils but also on basophils and mast cells (14) , and the existence of both the Siglec-8 and Siglec-8L isoforms was verified in human eosinophils, basophils, and mast cells (18, 19) . Most recently it was demonstrated that antibody cross-linking of Siglec-8 on human eosinophils induces caspase-dependent apoptosis in vitro (20) .
The search for Siglec ligands remains rather complex. Many of the Siglecs recognize ␣2-3-and ␣2-6-linked sialic acids (21, 22) , whereas others bind to other sialylated structures. For example, Siglec-1 has been shown to bind the highly glycosylated surface protein CD43 (23), the epithelial mucin MUC-1 (24) , and sialylated lipopolysaccharide (25) . Among a panel of glycans tested, Siglec-3 showed enhanced binding to a multivalent form of sialyl-Tn (NeuAc␣2-6GalNAc) disaccharides (26) . Siglec-7 binds to GD3 ganglioside, LSTb oligosaccharide, sialyl Lewis a , and NeuAc␣2-8NeuAc, whereas Siglec-9 preferentially binds GD1a ganglioside and LSTc oligosaccharide (5, 27, 28) . For Siglec-8, it has been shown that red blood cell rosettes are formed with Siglec-8, and neuraminidase treatment alters rosette formation (14, 15) . Specific structures shown to bind Siglec-8 include forms of sialic acid that are linked ␣2-3 or ␣2-6 to Gal␤1-4GlcNAc (15) . In a more comprehensive evaluation of binding specificities, 10 Siglec-Ig chimeras were screened for binding to 28 different sialosidestreptavidin-alkaline phosphatase probes, and a wide range of binding patterns were observed, but there was no clear binding preference for .
The Consortium for Functional Glycomics was funded as a large research initiative by the National Institutes of General Medical Sciences to facilitate research efforts focused on improving the understanding of the mechanisms by which glycanbinding proteins mediate cell communication. The Consortium is integrating the efforts of several scientific cores and participating investigators to achieve these aims. Among several cores is the protein-carbohydrate interaction core H and carbohydrate synthesis protein expression core D. These cores have developed a high throughput screening platform for identifying glycan-binding protein-ligand interactions using a streptavidin/biotin-based glycan array containing ϳ180 different glycan structures immobilized as biotinylated glycosides on a 384-well streptavidin-coated plate. This was developed as an expansion of previous efforts (29) and in conjunction with the carbohydrate synthesis core D to determine the glycan binding specificity of glycan-binding proteins. A secondary analysis method was also used to quantitate the relative binding affinities of candidate ligands by surface plasmon resonance. Here we report that these and other approaches have been used to determine that Siglec-8 is a highly specific lectin, binding preferentially to the sLe x structure bearing an additional sulfate ester on the galactose 6-hydroxyl, namely NeuAc␣2-3(6-O-sulfo)Gal␤1-4[Fuc␣1-3]GlcNAc, also referred to in the literature as 6Ј-sulfo-sLe x , which is a structure closely related to 6-sulfo-sLe x , a candidate ligand for L-selectin.
EXPERIMENTAL PROCEDURES
Siglec-8-Ig Chimera-The extracellular domain of Siglec-8 was inserted in-frame with a Factor Xa cleavage site and the Fc portion of human IgG 1 , expanded in electroporated CHOEA1 cells, and then purified from supernatants (final concentration, 2.4 mg/ml) using protein A-Sepharose as described previously (14) .
Glycomics Consortium Screening for Siglec-8 Ligands-Biotinylated glycosides (30) were coated in replicates of n ϭ 3 on streptavidin-coated microtiter plates (Pierce Reacti-Bind TM NeutrAvidin TM coated highbinding capacity black 384-well plates, product number 15513). Each well was incubated overnight at 4°C with 30 pmol/well of glycoside in 25 l of phosphate-buffered saline (PBS), pH 7.4. The plates were washed three times with 100 l of PBS using an automated plate washer (Molecular Devices, Sunnyvale, CA) and stored sealed at 4°C in 25 l/well PBS with 0.1% azide until use. Prior to assay, the plates were washed three times with 100 l/well wash buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 2 mM MgCl 2 , and 0.05% Tween 20) . A stock solution of Siglec-8-Ig (30 g/ml) was added to each well in 25 l of binding buffer (wash buffer plus 1% bovine serum albumin) and incubated at room temperature for 1 h. The plates were washed three times with 100 l/well wash buffer and incubated for 1 h with 25 l/well goat anti-human IgG-Alexa 488 (catalogue number A11013, Molecular Probes, Eugene, OR) at 5 g/ml in binding buffer. The plates were washed and read in 25 l of wash buffer on a Victor 2 TM 1420 Multilabel Counter (PerkinElmer Life Sciences) at excitation 485/emission 535. The glycosides probed are listed in Fig. S1 of the supplemental materials.
Measurement of Siglec-8-Ig Binding Affinity Using Surface Plasmon Resonance-All surface plasmon resonance (SPR) experiments were performed at 25°C on a Biacore 3000 instrument (Biacore Inc., Piscataway, NJ). Biotinylated glycosides were captured on research grade streptavidin-coated sensor chips (Sensor Chip SA, Biacore Inc.) that were pretreated according to the manufacturer's instructions. A solution of each biotinylated glycoside (10 fmol/l) was injected at 2 l/min in PBS, pH 7.4, containing 0.005% Tween 20 (running buffer) for varying lengths of time (3-7 min) until an optimal amount of glycan was captured on each independent surface. Three related glycosides were studied using one streptavidin sensor chip. A control (non-binding) glycan, LacNAc (Gal␤1-4GlcNAc), was also captured on the same sensor chip, and the specific binding of Siglec-8-Ig for the test glycans was measured using the in-line reference subtraction feature of the Biacore 3000 instrument. Increasing concentrations of Siglec-8-Ig (0.1-18 M) were injected at a flow rate of 60 l/min over all four surfaces of the sensor chip. Bound Siglec-8-Ig was found to elute with normal buffer flow after the injection was complete. The equilibrium binding data of Siglec-8-Ig were analyzed by non-linear curve fitting using the BIAevaluation software (Biacore Inc.).
Binding of Siglec-8-Ig to Aminoalkyl Glycosides Immobilized on Activated (N-hydroxysuccinimidyl) Glass Surfaces-
The N-succinimidylactivated glass slides (kindly provided by Schott-North America, Duryea, PA) were found to be compatible with the consortium library by coupling amino-terminated glycans and are currently being evaluated for a printed version of the consortium glycan array. A description of the printing and evaluation of the full array in this format has just been published elsewhere.
2 Fluorescein isothiocyanate-labeled goat antihuman IgG (Fc-specific) was from Jackson Immunoresearch (West Grove, PA). Aminopropyl glycosides were prepared as described previously (29, 31) . Amino hexylglucoside was synthesized as described (32) .
Aminoalkyl glycosides were covalently immobilized on N-succinimidyl-activated glass (Schott-Nexterion Slide H) using the manufacturer's protocols. All procedures were performed at ambient temperature. Briefly, each aminoalkyl glycoside was prepared at a series of concentrations ranging from 0.5 M to 1 mM in 300 mM sodium phosphate buffer, pH 8.5, 0.005% Tween 20 (spotting buffer). Drops (ϳ0.3 l) of each glycan at each concentration were hand-spotted in quadruplicate on the slide surface in a humid chamber. After spotting, the slide was maintained for an additional hour in the humid chamber and then transferred to a desiccated chamber for 16 h. The slide was then immersed in 50 mM ethanolamine, 50 mM sodium borate, pH 9.0, for 1 h, rinsed with water, dried under a stream of microfiltered air, and stored desiccated.
A solution of 100 g/ml Siglec-8-Ig and 50 g/ml fluorescein isothiocyanate-labeled goat anti-human IgG (Fc-specific) in Dulbecco's PBS containing 0.005% Tween 20 was incubated for 30 min at 37°C to allow complexes to form. The glycan-derivatized slide was immersed in PBS containing 0.01% Tween, drained, and then overlaid with the Siglec-8-Ig-fluorescein isothiocyanate antibody conjugate. After 2 h in a dark humid chamber, the slide was washed by successive immersion in PBS/0.01% Tween (three times) and water/0.01% Tween (twice). The slide was briefly rinsed with distilled water and dried under microfiltered air. An image of the bound fluorescence was obtaining using a microarray scanner (ScanArray Express, PerkinElmer Life Sciences). The integrated spot intensities were determined using Metamorph software (Universal Imaging, Downingtown, PA).
FIG. 2. Structures of glycans used to verify specificity of Siglec-8-Ig binding. These included 6-sulfo-sLe
x , 6Ј-sulfo-sLe x , and sLe x . Sia, sialic acid. 
RESULTS
Glycan Array Screening-Using the glycan array available through the Consortium for Functional Glycomics, experiments were initiated to identify compounds that selectively and specifically bind to Siglec-8. Using Siglec-8-Ig fusion protein, a panel of 172 carbohydrate-based structures (see Fig. S1 of the supplemental materials) was screened for specific Siglec-8 binding. As shown in Fig. 1 , Siglec-8-Ig fusion protein had high affinity (12:1 signal-to-noise binding) for structure 181, also know as 6Ј-sulfo-sLe x or NeuAc␣2-3(6-O-Su)Gal␤1-4(Fuc␣1-3)GlcNAc␤1-O(CH 2 ) 3 NH-CO(CH 2 ) 5 NH-biotin (Fig. 2) . Of additional relevance was that closely related structures to 181, such as structure 182, also known as 6-sulfo-sLe x NeuAc␣2-3Gal␤1-4(Fuc␣1-3)(6-O-Su)GlcNAc␤1-O(CH 2 ) 3 NH-CO(CH 2 ) 5 NH-biotin, which only differs from structure 181 by the location of the 6-O-Su (Fig. 2) , and structure 108, also known as sLe x or NeuAc␣2-3Gal␤1-4(Fuc␣1-3)GlcNAc␤1-O(CH 2 ) 2 NHCO(CH 2 ) 5 NHCO(CH 2 ) 5 NH-biotin, had minimally increased binding affinity (1.2:1 and 0.8:1 signal-to-noise binding, respectively) for Siglec-8. The spacer arm itself, -O(CH 2 ) 3 NH-CO(CH 2 ) 5 NH-biotin, found on many of the other non-binding structures, cannot explain the binding activity for Siglec-8. Taken together, this information demonstrates that the 6-position O-linked sulfate on galactose is key to the specificity and affinity of this structure for Siglec-8 (Fig. 2) .
Validation of Glycan Array Results by SPR-The binding affinities of Siglec-8 for structures 108, 182, and 181 (Fig. 3 , a-c, respectively) were determined on a Biacore 3000 instrument using a streptavidin-coated sensor chip. LacNAc was captured on one surface of the sensor chip and used as negative control (data not shown). As shown in Fig. 3 , Siglec-8 showed specific binding, with very fast association and dissociation profiles only to the ligand 181. The sensorgrams showed that upon injection of the Siglec, binding rapidly reached equilibrium in the first few seconds, and the bound Siglec fell off rapidly after the injection was stopped. The apparent K d for binding of Siglec-8 to ligand 181 was between 2 and 2.5 M (Fig. 4) . Further Verification of the Glycan Array Results-Binding of Siglec-8-Ig precomplexed with fluorescein isothiocyanate antihuman Fc to aminopropyl glycosides immobilized on activated (N-hydroxysuccinimidyl) glass surfaces was also used to further verify the specificity of 6Ј-sulfo-sLe x as a Siglec-8 ligand. As shown in Fig. 5 , fluorescent signals were detected at immobilized concentrations of 6Ј-sulfo-sLe x as low as 5 pmol/spot. In contrast, sLe x and 6-sulfo-sLe x did not support any Siglec-8 binding at the highest concentration tested (300 pmol/spot).
DISCUSSION
Using a glycan array assembled by the Consortium for Functional Glycomics, 172 structures were screened for their ability to bind to Siglec-8-Ig fusion protein. By far the greatest binding was seen with ligand 181, which is 6Ј-sulfo-sLe x ( Figs. 1 and 2 ). Specificity was subsequently verified using SPR and a separate assay using immobilized glycans (Figs. 3-5 ). These three separate methods confirmed the specificity to be 6Ј-sulfo-sLe x and not closely related structures because Siglec-8-Ig fusion protein failed to bind to unsulfated sLe x as well as the closely related structure 6-sulfo-sLe
x . In addition, the specificity of binding, with reasonably high affinity (K d 2.3 M) to only one of 172 ligands tested, suggests that 6Ј-sulfo-sLe x is a strong candidate for being a Siglec-8 ligand. Because candidate ligands for most other Siglecs remain virtually unknown, it is difficult to compare the K d value for 6Ј-sulfo-sLex-Siglec-8 binding (2. for Siglec-8 versus other human Siglecs has not yet been explored, this is the first time this ligand has been suspected to bind to any of the Siglecs. The likely mouse ortholog for Siglec-8 is mSiglec-F (33), but it is currently unknown whether 6Ј-sulfosLe x is a ligand. However, additional experiments (data not shown) using an mSiglec-G-Ig fusion protein failed to show specific binding to 6Ј-sulfo-sLe x , providing some degree of selectivity of binding for Siglec-8. Additionally, it remains to be determined what role various components of 6Ј-sulfo-sLe x , such as fucose, play in binding. Finally, there are no known receptors for the structure, although initial studies suggested that 6Ј-sulfo-sLe x might serve as an L-selectin ligand (34) . However, subsequent studies found that 6-sulfo-sLe x rather than 6Ј-sulfo-sLe x is a preferred ligand (35) (36) (37) (38) . Considering that the Siglec-8-Ig fusion protein is bivalent, the rapid nature of binding seen in Fig. 3 seems unexpected. Furthermore, because the reagent used for calculation of dissociation rates is bivalent, it is unclear whether the dissociation rate of Siglec-8 monomer, when expressed on the surface of a cell, would be similar or different. It is possible that the two binding sites on each arm of the chimera associate and dissociate from the glycan with the same binding parameters, but this remains unclear.
Synthesis of 6Ј-sulfo-sLe x requires the presence of specific sulfotransferases in the Golgi apparatus of cells. Based on the known family of human Golgi-associated sulfotransferases (39 -41) , at least GST-1 (also known as keratin sulfate galactose 6-O sulfotransferase (KSGal6ST) and carbohydrate sulfotransferase 1 (CHST-1)), which is known to sulfate galactose residues linked to N-acetyl glucosamine, would likely be involved in the synthesis of 6Ј-sulfo-sLe x (Fig. 2) . These genes are located on chromosome 11p11.1-11.2, and studies report rather broad tissue distribution of CHST-1 (42, 43) , although KSGal6ST reportedly is expressed predominantly in brain tissue and to a lesser degree in skeletal muscle (44) . Methods such as immunohistochemistry would be useful in identifying tissue localization of 6Ј-sulfo-sLe x expression, but to date, there are no antibody reagents that can distinguish 6Ј-sulfo-sLe x from 6-sulfo-sLe x (45) . Previous studies with monoclonal antibodies suggest that cross-linking of Siglec-8 induces apoptosis on cells that express Siglec-8, such as human eosinophils (20) , so it is tempting to speculate that expression of Siglec-8 ligand in the central nervous system may be a way to eliminate inflammatory cells that have infiltrated the central nervous system. In summary, a Siglec-8-Ig chimeric protein was screened for binding to 172 different glycan structures immobilized as biotinylated glycosides. Among these, avid binding was detected to a single defined glycan, NeuAc␣2-3(6-O-sulfo)Gal␤1-4[Fuc␣1-3]GlcNAc, also referred to in the literature as 6Ј-sulfosLe
x . The data presented herein also demonstrate the utility and ease by which the Consortium for Functional Glycomics protein-carbohydrate interaction core H can readily be used to determine selective attachment of lectins, in this case a Siglec, to carbohydrate ligands. This rapid screening technique provides an initial method to define carbohydrate ligands for a wide range of structures and should prove useful for many such applications.
Note Added in Proof-Using a similar glycan array approach, it is now known that 6Ј-sulfo-sLe x is also a ligand for langerin (Galustian, C., Park, G. G., Chai, W., Kiso, M., Bruening, S. A., Kang, Y. S., Steinman, R. M., and 
